Related Experiment Video
Updated: Jun 3, 2026
Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease
Published on: April 28, 2023
Intratympanic gentamicin for Ménière's disease or syndrome
Bas Pullens1, Peter Paul van Benthem
1ENT Surgery, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht, Netherlands, 3584 CX.
Background:
Ménière's disease is characterised by three major symptoms: vertigo, deafness and tinnitus, which may be accompanied by aural fullness, all of which are discontinuous and variable in intensity. While discontinuous, these symptoms are synchronous. Intratympanic application of gentamicin, an ototoxic aminoglycoside, is a relatively new ablative treatment for vertigo in Ménière's disease with promising results.
Objectives:
To assess the effectiveness of intratympanic gentamicin in the treatment of vertigo in Ménière's disease.
Search Strategy:
We searched the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL); PubMed; EMBASE; CINAHL; Web of Science; BIOSIS Previews; Cambridge Scientific Abstracts; ISRCTN and additional sources for published and unpublished trials. The date of the most recent search was 30 June 2010.
Selection Criteria:
All randomised or quasi-randomised controlled trials of intratympanic gentamicin versus placebo, or versus another treatment for Ménière's disease.
Data Collection And Analysis:
Two review authors independently assessed trial quality and extracted data. We contacted study authors for further information.
Main Results:
We identified two trials, involving 50 participants, which fulfilled the inclusion criteria. Both of these trials are prospective, double-blind, placebo-controlled randomised clinical trials on the effect of intratympanic gentamicin on vertigo complaints. Both of these trials found a significant reduction in vertigo complaints in the gentamicin group when compared to the placebo group. Due to clinical heterogeneity we could not perform a meta-analysis.
Authors' Conclusions:
Based on the results of the two included studies, intratympanic gentamicin seems to be an effective treatment for vertigo complaints in Ménière's disease, but carries a risk of hearing loss.
Insights
Intratympanic gentamicin significantly reduces vertigo in Ménière's disease patients. However, this treatment carries a risk of hearing loss, requiring careful consideration.
Area of Science:
- Otolaryngology
- Neurology
- Pharmacology
Background:
- Ménière's disease presents with vertigo, deafness, and tinnitus.
- Intratympanic gentamicin is an emerging ablative therapy for Ménière's disease vertigo.
Purpose of the Study:
- To evaluate the efficacy of intratympanic gentamicin for Ménière's disease vertigo.
Main Methods:
- Systematic search of multiple databases for randomized controlled trials.
- Inclusion of trials comparing intratympanic gentamicin to placebo or other treatments.
- Independent quality assessment and data extraction by two reviewers.
Main Results:
- Two randomized, double-blind, placebo-controlled trials involving 50 participants were identified.
- Intratympanic gentamicin demonstrated a significant reduction in vertigo complaints compared to placebo.
- Meta-analysis was not possible due to clinical heterogeneity.
Conclusions:
- Intratympanic gentamicin appears effective for managing vertigo in Ménière's disease.
- A potential risk of hearing loss is associated with this treatment.
Related Concept Videos
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
01:26Mitral Stenosis III: Medical Management
01:27Cryptococcal Meningitis